J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Matthew P. Goetz,Vera J. Suman,Joel M. Reid,Don W. Northfelt,Michael A. Mahr,Andrew T. Ralya,Mary J. Kuffel,Sarah A. Buhrow,Stephanie L. Safgren,Renee M. McGovern,John L. Black,Travis J. Dockter,Tufia C. Haddad,Charles Erlichman,Alex A. Adjei,DW Visscher,Zachary R. Chalmers,Garrett M. Frampton,Benjamin R. Kipp,Minetta C. Liu,John R. Hawse,James H. Doroshow,Jerry M. Collins,Howard Streicher,Matthew M. Ames,James N. Ingle +25 more
TL;DR: In endocrine-refractory metastatic breast cancer, Z-endoxifen provides substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity, and promising antitumor activity.
Journal ArticleDOI
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
Kristin A. Bradley,Ian F. Pollack,Joel M. Reid,Peter C. Adamson,Matthew M. Ames,Gilbert Vezina,Susan M. Blaney,Percy Ivy,Tianni Zhou,Mark Krailo,Gregory H. Reaman,Minesh P. Mehta +11 more
TL;DR: The maximum tolerated dose of MGd and the recommended phase II dose was 4.4 mg/kg when administered as a daily intravenous bolus in conjunction with 6 weeks of involved field radiation therapy for pediatric intrinsic pontine gliomas.
Journal ArticleDOI
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Eudocia Q. Lee,Vinay K. Puduvalli,Joel M. Reid,John G. Kuhn,Kathleen R. Lamborn,Timothy F. Cloughesy,Susan M. Chang,Jan Drappatz,Jan Drappatz,W. K. Alfred Yung,Mark R. Gilbert,H. Ian Robins,Frank S. Lieberman,Andrew B. Lassman,Renee M. McGovern,Jihong Xu,Serena Desideri,Xiabu Ye,Matthew M. Ames,Igor Espinoza-Delgado,Michael D. Prados,Patrick Y. Wen +21 more
TL;DR: Vorinostat in combination with temozolomide is well tolerated in patients with high-grade glioma and a phase I/II trial of vor inostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.
Journal ArticleDOI
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois,Yael P. Mosse,Elizabeth Fox,Rachel A. Kudgus,Joel M. Reid,Renee M. McGovern,S. Groshen,Rochelle Bagatell,John M. Maris,Clare J. Twist,Kelly C. Goldsmith,M. Meaghan Granger,Brian Weiss,Julie R. Park,Margaret E. Macy,Susan L. Cohn,Gregory A. Yanik,Lars M. Wagner,Randall Hawkins,Jesse Courtier,Hollie Lai,Fariba Goodarzian,Hiroyuki Shimada,Najee Boucher,Scarlett Czarnecki,Chunqiao Luo,Denice D. Tsao-Wei,Katherine K. Matthay,Araz Marachelian +28 more
TL;DR: This combination of alisertib tablets with irinotecan and temozolomide shows antitumor activity, particularly in patients with MYCN nonamplified tumors, which expands the population able to be treated with this agent.
Journal ArticleDOI
Controlled Delivery of Vancomycin via Charged Hydrogels
Carl T. Gustafson,Felix Boakye-Agyeman,Cassandra L. Brinkman,Joel M. Reid,Robin Patel,Zeljko Bajzer,Mahrokh Dadsetan,Michael J. Yaszemski +7 more
TL;DR: It is demonstrated that OPF/SMA hydrogels are appropriate candidates to deliver local antibiotic therapy for prophylaxis of surgical site infection and the antimicrobial activity of released vancomycin is equivalent to stock vancomYcin in inhibiting the growth of colonies of a clinically derived strain of methicillin-resistant Staphylococcus aureus.